VRTX [NASD]
Vertex Pharmaceuticals Incorporated
IndexS&P 500 P/E23.76 EPS (ttm)12.67 Insider Own0.10% Shs Outstand256.50M Perf Week-4.34%
Market Cap77.98B Forward P/E19.09 EPS next Y15.77 Insider Trans-24.89% Shs Float256.21M Perf Month6.33%
Income3.27B PEG2.93 EPS next Q3.51 Inst Own95.70% Short Float / Ratio1.03% / 1.83 Perf Quarter-1.67%
Sales8.70B P/S8.96 EPS this Y-12.50% Inst Trans1.21% Short Interest2.63M Perf Half Y6.27%
Book/sh50.80 P/B5.93 EPS next Y7.74% ROA21.80% Target Price329.71 Perf Year25.58%
Cash/sh37.72 P/C7.98 EPS next 5Y8.10% ROE28.50% 52W Range225.28 - 325.19 Perf YTD6.00%
Dividend- P/FCF20.45 EPS past 5Y85.00% ROI22.50% 52W High-5.87% Beta0.46
Dividend %- Quick Ratio4.60 Sales past 5Y34.80% Gross Margin88.00% 52W Low35.88% ATR6.86
Employees3900 Current Ratio4.70 Sales Q/Q17.60% Oper. Margin47.70% RSI (14)49.01 Volatility2.57% 2.18%
OptionableYes Debt/Eq0.03 EPS Q/Q9.30% Profit Margin37.60% Rel Volume0.82 Prev Close301.02
ShortableYes LT Debt/Eq0.03 EarningsFeb 07 AMC Payout0.00% Avg Volume1.44M Price306.10
Recom2.20 SMA20-0.29% SMA500.18% SMA2005.79% Volume160,367 Change1.69%
Jan-18-23Initiated Canaccord Genuity Hold $311
Jan-17-23Upgrade SVB Leerink Mkt Perform → Outperform $374
Dec-19-22Downgrade Jefferies Buy → Hold $340
Jul-13-22Initiated Cantor Fitzgerald Overweight $365
Jun-01-22Upgrade Maxim Group Hold → Buy $325
May-23-22Initiated SVB Leerink Mkt Perform $265
May-06-22Downgrade Robert W. Baird Outperform → Neutral $250
May-03-22Upgrade Morgan Stanley Underweight → Equal-Weight $250
Feb-03-22Downgrade RBC Capital Mkts Outperform → Sector Perform $269
Jan-27-22Reiterated Wolfe Research Outperform $271 → $282
Show Previous Ratings
Feb-03-23 02:02PM
09:37AM
Feb-02-23 10:00AM
09:53AM
05:52AM
05:45PM Loading…
Feb-01-23 05:45PM
05:52AM
Jan-31-23 04:14PM
10:00AM
10:00AM
Jan-30-23 05:50PM
09:55AM
09:33AM
08:58AM
Jan-27-23 10:11AM
09:53AM Loading…
09:53AM
09:36AM
09:18AM
08:20AM
06:50AM
Jan-26-23 10:01AM
09:42AM
09:17AM
Jan-25-23 05:20PM
10:02AM
09:53AM
09:19AM
08:57AM
08:35AM
Jan-24-23 05:50PM
10:13AM Loading…
10:13AM
09:35AM
09:16AM
08:41AM
08:27AM
Jan-23-23 12:37PM
09:53AM
09:37AM
09:24AM
Jan-21-23 06:34PM
09:10AM
06:55AM
Jan-20-23 10:23AM
09:45AM
09:15AM
08:56AM
08:20AM
08:20AM
Jan-19-23 09:57PM
06:10PM
10:00AM
09:47AM
09:38AM
09:17AM
08:21AM
08:17AM
05:30AM
Jan-18-23 07:10PM
05:50PM
04:47PM
09:45AM
08:19AM
06:00AM
12:31AM
Jan-17-23 10:09PM
08:32PM
08:00AM
Jan-16-23 08:30AM
05:30AM
Jan-14-23 06:15AM
06:00AM
Jan-13-23 11:54AM
07:00AM
Jan-12-23 09:40AM
08:28AM
07:45AM
05:52AM
Jan-11-23 03:03PM
08:44AM
05:52AM
05:10AM
Jan-10-23 05:50PM
11:55AM
08:15AM
05:50AM
Jan-09-23 08:00AM
06:00AM
Jan-08-23 09:45AM
Jan-07-23 06:15AM
05:30AM
Jan-06-23 06:50PM
Jan-05-23 12:05PM
07:00AM
Jan-04-23 08:00AM
05:52AM
05:30AM
05:06AM
Jan-03-23 05:50PM
10:45AM
05:52AM
Vertex Pharmaceuticals Incorporated, a biotechnology company, engages in developing and commercializing therapies for treating cystic fibrosis. The company markets SYMDEKO/SYMKEVI, ORKAMBI, and KALYDECO to treat patients with cystic fibrosis who have specific mutations in their cystic fibrosis transmembrane conductance regulator gene; and TRIKAFTA for the treatment of patients with CF 6 years of age or older who have at least one F508del mutation. Its pipeline includes VX-864 for the treatment of AAT deficiency, which is in Phase 2 clinical trial; VX-147 for the treatment of APOL1-mediated focal segmental glomerulosclerosis, or FSGS, and other serious kidney diseases which is in Phase 2 clinical trial; VX- 880, treatment for Type 1 Diabetes which is in Phase 1/2 clinical trial; VX-548, a NaV1.8 inhibitor for treatments of acute, neuropathic, musculoskeletal pain which is in Phase 2 clinical trial; and CTX001 for the treatment severe SCD and TDT which is in Phase 3 clinical trial. The company sells its products primarily to specialty pharmacy and specialty distributors in the United States, as well as specialty distributors and retail chains, and hospitals and clinics internationally. It has collaborations with Affinia Therapeutics, Inc.; Arbor Biotechnologies, Inc.; CRISPR Therapeutics AG.; Kymera Therapeutics, Inc.; Mammoth Biosciences, Inc.; Moderna, Inc.; Obsidian Therapeutics, Inc.; and Skyhawk Therapeutics, Inc.; as well as Ribometrix, Inc.; Genomics plc; Merck KGaA; Darmstadt, Germany, and X-Chem, Inc. Vertex Pharmaceuticals Incorporated was founded in 1989 and is headquartered in Boston, Massachusetts.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
SACHS BRUCE IDirectorJan 31Option Exercise72.141,20086,56842,410Feb 02 04:14 PM
Sanna BastianoEVP, Cell & Genetic TherapiesJan 31Sale325.0010634,45037,998Feb 02 04:18 PM
SACHS BRUCE IDirectorJan 31Sale325.011,200390,01241,210Feb 02 04:14 PM
CARNEY LLOYDDirectorJan 30Sale320.522,700865,4064,150Jan 31 04:45 PM
Lee YuchunDirectorJan 27Option Exercise72.141,429103,0883,304Jan 31 04:42 PM
Lee YuchunDirectorJan 27Sale322.031,429460,1771,875Jan 31 04:42 PM
Lee YuchunDirectorJan 26Option Exercise72.144,000288,5605,875Jan 27 04:18 PM
Lee YuchunDirectorJan 26Sale318.334,0001,273,3221,875Jan 27 04:18 PM
Lee YuchunDirectorJan 25Option Exercise72.144,000288,5605,875Jan 27 04:18 PM
Lee YuchunDirectorJan 25Sale313.964,0001,255,8521,875Jan 27 04:18 PM
Kewalramani ReshmaCEO & PresidentJan 25Sale315.0510,0003,150,50089,598Jan 27 04:13 PM
Lee YuchunDirectorJan 24Option Exercise72.144,000288,5605,875Jan 25 04:08 PM
Lee YuchunDirectorJan 24Sale312.694,0001,250,7531,875Jan 25 04:08 PM
Lee YuchunDirectorJan 23Option Exercise72.142,129153,5864,004Jan 25 04:08 PM
Lee YuchunDirectorJan 23Sale312.022,129664,2911,875Jan 25 04:08 PM
Lee YuchunDirectorJan 18Option Exercise72.1444231,8862,317Jan 19 04:07 PM
Lee YuchunDirectorJan 18Sale312.17442137,9791,875Jan 19 04:07 PM
Lee YuchunDirectorJan 17Option Exercise72.144,000288,5605,875Jan 19 04:07 PM
Lee YuchunDirectorJan 17Sale312.034,0001,248,1201,875Jan 19 04:07 PM
ALTSHULER DAVIDEVP, Global Research and CSONov 15Sale308.613410,49336,077Nov 17 04:08 PM
ALTSHULER DAVIDEVP, Global Research and CSONov 07Option Exercise187.531,303244,35237,380Nov 09 04:40 PM
ALTSHULER DAVIDEVP, Global Research and CSONov 07Sale303.041,303394,85936,077Nov 09 04:40 PM
Sanna BastianoEVP, Cell & Genetic TherapiesNov 02Sale312.64320100,04538,104Nov 03 04:05 PM
Bhatia Sangeeta N.DirectorOct 24Sale310.00621192,5104,040Oct 26 04:05 PM
Sanna BastianoEVP, Cell & Genetic TherapiesOct 18Sale300.311,791537,86039,192Oct 20 04:11 PM
Arbuckle Stuart AEVP, COOAug 15Option Exercise155.576,5711,022,25067,451Aug 17 05:39 PM
Liu JoySVP, General CounselAug 15Sale303.903,7471,138,7239,605Aug 17 05:36 PM
Kewalramani ReshmaCEO & PresidentAug 15Sale305.0611,6893,565,84699,598Aug 17 05:40 PM
Arbuckle Stuart AEVP, COOAug 15Sale303.9322,1736,738,99145,278Aug 17 05:39 PM
Arbuckle Stuart AEVP, COOAug 10Option Exercise155.57649,95661,060Aug 12 04:05 PM
Arbuckle Stuart AEVP, COOAug 10Sale300.4018054,07360,880Aug 12 04:05 PM
Liu JoySVP, General CounselAug 10Sale300.323610,81213,352Aug 12 04:05 PM
Arbuckle Stuart AEVP, COOAug 09Option Exercise155.571,926299,62866,686Aug 10 04:06 PM
Liu JoySVP, General CounselAug 09Sale300.00946283,80013,388Aug 10 04:06 PM
Arbuckle Stuart AEVP, COOAug 09Sale300.675,6901,710,81760,996Aug 10 04:06 PM
Tatsis OuraniaEVP, Chief Reg. & Quality Off.Aug 09Sale298.971,400418,55746,090Aug 10 04:06 PM
ALTSHULER DAVIDEVP, Global Research and CSOAug 08Option Exercise187.531,304244,53937,381Aug 10 04:06 PM
Bhatia Sangeeta N.DirectorAug 08Sale293.03621181,9724,661Aug 10 04:07 PM
ALTSHULER DAVIDEVP, Global Research and CSOAug 08Sale292.541,304381,46936,077Aug 10 04:06 PM
Bhatia Sangeeta N.DirectorJul 29Sale278.77621173,1165,282Aug 02 04:16 PM
LEIDEN JEFFREY MExecutive ChairmanJul 25Option Exercise91.0560,3425,494,139134,502Jul 27 04:17 PM
LEIDEN JEFFREY MExecutive ChairmanJul 25Sale281.38132,07937,164,4812,423Jul 27 04:17 PM
ALTSHULER DAVIDEVP, Global Research and CSOJul 19Option Exercise174.3317,7653,096,94853,942Jul 21 04:48 PM
ALTSHULER DAVIDEVP, Global Research and CSOJul 19Sale288.6517,8655,156,73036,077Jul 21 04:48 PM
Kewalramani ReshmaCEO & PresidentJun 24Sale291.3011,6893,405,006111,153Jun 28 04:05 PM
Sanna BastianoEVP, Cell & Genetic TherapiesMay 16Sale252.834511,37741,749May 18 04:22 PM
Arbuckle Stuart AEVP, COOMay 16Sale251.1913333,40864,760May 18 04:21 PM
Liu JoySVP, General CounselMay 16Sale252.8813333,63314,334May 18 04:18 PM
Sanna BastianoEVP, Cell & Genetic TherapiesMay 04Sale275.09369,90341,660May 06 04:05 PM
Arbuckle Stuart AEVP, COOMay 02Sale263.9830680,77864,760May 04 05:21 PM
Sanna BastianoEVP, Cell & Genetic TherapiesMay 02Sale259.1632082,93041,696May 04 05:10 PM
Bhatia Sangeeta N.DirectorMay 02Sale258.94737190,8425,903May 04 05:09 PM
WAGNER CHARLES F JREVP & Chief Financial OfficerMay 02Sale258.8334388,77842,730May 04 05:07 PM
Liu JoySVP, General CounselApr 29Sale275.4112033,04914,334May 03 04:28 PM
Ambrose KristenSVP & Chief Accounting OfficerApr 25Sale269.5532788,1433,496Apr 27 04:05 PM
Lee YuchunDirectorApr 18Option Exercise81.542,000163,0803,875Apr 20 04:05 PM
Lee YuchunDirectorApr 18Sale284.232,000568,4671,875Apr 20 04:05 PM
Lee YuchunDirectorApr 14Option Exercise81.542,000163,0803,875Apr 18 04:05 PM
Lee YuchunDirectorApr 14Sale289.062,000578,1171,875Apr 18 04:05 PM
Lee YuchunDirectorApr 13Option Exercise81.542,000163,0803,875Apr 14 04:35 PM
Lee YuchunDirectorApr 13Sale287.502,000575,0101,875Apr 14 04:35 PM
LEIDEN JEFFREY MExecutive ChairmanApr 13Sale289.0415,7894,563,65374,160Apr 14 04:35 PM
Lee YuchunDirectorApr 12Option Exercise81.542,000163,0803,875Apr 14 04:35 PM
Lee YuchunDirectorApr 12Sale281.032,000562,0511,875Apr 14 04:35 PM
Lee YuchunDirectorApr 11Option Exercise81.542,000163,0803,875Apr 12 04:07 PM
Lee YuchunDirectorApr 11Sale280.302,000560,5991,875Apr 12 04:07 PM
MCGLYNN MARGARET GDirectorApr 08Option Exercise127.545,000637,7006,099Apr 12 04:05 PM
Bhatia Sangeeta N.DirectorApr 08Option Exercise125.711,907239,7297,098Apr 12 04:05 PM
Lee YuchunDirectorApr 08Option Exercise81.542,000163,0803,875Apr 12 04:07 PM
Lee YuchunDirectorApr 08Sale278.572,000557,1411,875Apr 12 04:07 PM
Bhatia Sangeeta N.DirectorApr 08Sale280.201,907534,3415,191Apr 12 04:05 PM
MCGLYNN MARGARET GDirectorApr 08Sale280.225,0001,401,0801,099Apr 12 04:05 PM
Lee YuchunDirectorApr 07Option Exercise81.542,000163,0803,875Apr 08 05:57 PM
Lee YuchunDirectorApr 07Sale274.862,000549,7201,875Apr 08 05:57 PM
Sanna BastianoEVP, Cell & Genetic TherapiesApr 07Sale276.18561154,93542,782Apr 08 04:34 PM
Lee YuchunDirectorApr 06Option Exercise81.542,000163,0803,875Apr 08 05:57 PM
Lee YuchunDirectorApr 06Sale271.622,000543,2431,875Apr 08 05:57 PM
Lee YuchunDirectorApr 05Option Exercise81.542,000163,0803,875Apr 06 04:59 PM
Sanna BastianoEVP, Cell & Genetic TherapiesApr 05Sale275.233,163870,55243,343Apr 06 05:02 PM
Lee YuchunDirectorApr 05Sale272.502,000544,9931,875Apr 06 04:59 PM
Lee YuchunDirectorApr 04Option Exercise81.542,000163,0803,875Apr 06 04:59 PM
Sanna BastianoEVP, Cell & Genetic TherapiesApr 04Sale267.71562150,45246,506Apr 06 05:02 PM
Lee YuchunDirectorApr 04Sale267.722,000535,4311,875Apr 06 04:59 PM
WAGNER CHARLES F JREVP & Chief Financial OfficerApr 01Sale264.762,582683,60243,620Apr 05 04:06 PM
MCGLYNN MARGARET GDirectorMar 31Option Exercise127.545,000637,7006,099Apr 04 04:05 PM
MCGLYNN MARGARET GDirectorMar 31Sale262.275,0001,311,3461,099Apr 04 04:05 PM
Tatsis OuraniaEVP, Chief Reg. & Quality Off.Mar 17Sale250.112,833708,57247,356Mar 21 04:15 PM
WAGNER CHARLES F JREVP & Chief Financial OfficerMar 17Sale250.153,171793,21846,202Mar 21 04:12 PM
Sanna BastianoEVP, Cell & Genetic TherapiesMar 17Sale250.062,122530,62748,412Mar 21 04:10 PM
Tatsis OuraniaEVP, Chief Reg. & Quality Off.Feb 25Sale230.9532575,05850,189Feb 28 05:27 PM
Tatsis OuraniaEVP, Chief Reg. & Quality Off.Feb 18Sale231.00519119,88953,104Feb 22 05:03 PM
ALTSHULER DAVIDEVP, Global Research and CSOFeb 18Sale230.974,312995,94949,687Feb 22 04:51 PM
ALTSHULER DAVIDEVP, Global Research and CSOFeb 14Sale232.022,444567,05757,438Feb 16 04:05 PM
ALTSHULER DAVIDEVP, Global Research and CSOFeb 11Sale235.022,297539,83759,882Feb 14 04:11 PM